80 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Unknown  Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: GreenGene™ F
22 Not yet recruiting Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Canadian Patients With Hemophilia
Condition: Hemophilia A
Intervention:
23 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
24 Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
25 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
26 Not yet recruiting Improved Factor VIII Inhibitor Evaluation
Conditions: Hemophilia;   Hemophilia A
Intervention:
27 Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
28 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
29 Recruiting Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant factor VIII (rFVIII)
30 Recruiting Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
31 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
32 Recruiting Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII)
33 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
34 Recruiting Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Concizumab;   Drug: placebo
35 Recruiting A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
Condition: Hemophilia A
Intervention: Drug: Coagulation Products
36 Recruiting Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Intervention: Biological: OBIZUR
37 Recruiting Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human cl rhFVIII
38 Recruiting A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients From ≥6 Months Old to <12 Years Old With Inhibitors to Factor VIII or IX
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention: Biological: Coagulation FVIIa (Recombinant)
39 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
40 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years